Search Results

You are looking at 191 - 200 of 782 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

James L. Mohler

large reduction in biochemical recurrence. 4 In RTOG 86-10, which evaluated RT after 3 months of ADT, the combination led to a reduction in the rates of prostate-specific antigen (PSA) failure, metastases, and cancer-specific mortality and showed a

Full access

Azeez Farooki

osteoclast targeted therapy for the prevention of bone metastases in prostate cancer. Metastatic Bone Disease: Focus on Imaging The most common site of metastases is the skeleton, with bone lesions causing SREs in many patients with breast, prostate

Full access

David B. Shultz, John C. Grecula, James Hayman, Maximilian Diehn, and Billy W. Loo Jr

ipsilateral hemithorax, which may include malignant pleural or pericardial effusion or hematogenous metastases (Tany,Nany,M1a/b; T3-4 because of multiple lung nodules). 10 Limited-Stage SCLC Approximately one-third of patients present with limited

Full access

NCCN Guidelines Insights: Cervical Cancer, Version 1.2020

Featured Updates to the NCCN Guidelines

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Sarah Bean, Kristin Bradley, Susana M. Campos, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Rachel Sisodia, Todd Tillmanns, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, and Angela D. Motter

use the Silva system in clinical practice. However, the available data suggest that the system may more accurately stratify patients with HPV-related EAC by risk of metastases, recurrence, and death than the current clinicopathologic features that are

Full access

Stacey Shiovitz and Keith D. Eaton

Oncology (NCCN Guidelines) for NSCLC [NSCLC-11], 3 patients with oligometastatic disease, specifically a single adrenal or brain lesion, may benefit from a different treatment approach compared with those with advanced or widespread metastases (to view the

Full access

Boda Guo and Ming Liu

African American patients had roughly 3 times higher rates of papillary RCC across disease stages than non–African American patients. 3 Finally, the prognosis of RCC with lymph node metastasis is different from that with distant metastases. 4 It would

Full access

William C. Huang and Bernard H. Bochner

dissection, and bilateral uretero-enterostomy . J Urol 1950 ; 63 : 242 – 260 . 4. Mills RD Turner WH Fleischmann A . Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy

Full access

Kelly N. Fitzgerald and Chung-Han Lee

% (95% CI, 32%–62%) and a tolerable adverse effect profile. 28 Genetic testing can also help first-line therapy selection if it leads to clarification of RCC histologic subtype. Disease Location and Burden The distribution and size of metastases and

Full access

Dylan Joseph Peterson, Nicolai Patrick Ostberg, Selen Bozkurt, James D. Brooks, Douglas W. Blayney, and Tina Hernandez-Boussard

preventable ED or IP visits within 180 days of starting chemotherapy (AUROC: 0.799). For this model, predictors of ED or IP visits included liver or brain metastases (ORs 1.12 and 1.07, respectively), prior ED visits (OR 1.09), white race (OR 0.90), worse

Full access

Meghan J. Mooradian, Kenneth Shermock, David Merola, Brian Seal, Candice Yong, and Lance Brannman

cancers (pre- and post-index periods), lung resection, SCLC treatments (drugs or prophylactic cranial irradiation), lung metastases, or palliative care only (≤10 radiotherapy claims with no chemotherapy during the post-index period). Patients with a